



TO: NQF Members and Public

FR: NQF Staff

RE: *Review of Patient Reported Outcomes in Performance Measurement*

DA: October 24, 2012

### **Background**

Patient and family engagement is increasingly acknowledged as a key component of a comprehensive strategy, including performance improvement and accountability, in achieving a high quality, affordable health system. Emerging evidence affirms patients who are engaged in their care tend to experience better outcomes and choose less costly but effective interventions, such as physical therapy for low back pain, after undergoing a process of shared decision-making. Promising approaches to authentically involve patients and their families at multiple levels are being implemented across the country including serving on governance boards at hospitals and contributing to system and practice redesign to make care safer and more patient-centric.

Historically, with the exception of collecting feedback on satisfaction or experience with care, patients remain an untapped resource in the assessment of the quality of care and that of long-term support services. Patients are a valuable and arguably the authoritative source of information on other outcomes beyond experience including: health-related quality of life, symptom and symptom burden, and health-related behaviors. Therefore, interest in performance measures based on patient-reported outcomes is increasing.

The project goals were to:

- Identify key characteristics for selecting PRO instruments (PROMs) to be used in performance measures (PRO-PMs);
- Identify any unique considerations for evaluating PRO-PMs for NQF endorsement and use in accountability and performance improvement applications; and
- Lay out the pathway to move from PROMs to NQF-endorsed PRO-PMs.

## **Review and Comment**

The Expert Panel's recommendations are included in the draft document, *Patient Reported Outcomes in Performance Measurements*. The draft report is posted on the NQF web site for review and comment only—not voting. The recommendations include a suggested pathway to move from PRO concept to an endorsed PRO-PM and some modifications related to NQF criteria for evaluating performance measures when considering PRO-PMs for NQF endorsement. Of particular note are recommendations to require: evidence that persons form the target population find the PRO meaningful; evidence that a PRO is responsive to intervention; and reliability and validity testing of both the PROM and the PRO-PM.

You may post your comments and view the comments of others on the NQF website.

**NQF Member and Public comments must be submitted no later than 6:00 PM ET, November 23, 2012.**

NQF is now using a program that facilitates electronic submission of comments on this draft report. **All comments must be submitted using the online submission process.**

Supporting documents related to your comments may be submitted by e-mail to [pro@qualityforum.org](mailto:pro@qualityforum.org) with "PRO Report" in the subject line and your contact information in the body of the e-mail.

Thank you for your interest in the NQF's work. We look forward to your review and comments.



NATIONAL  
QUALITY FORUM

**National Quality Forum**

**Patient Reported Outcomes (PROs) in Performance Measurement**

**Draft Report for Comment**

**10/24/12**

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

## Table of Contents

INTRODUCTION.....	1
US Healthcare: Performance Improvement & Accountability.....	1
Achieving Performance Improvement & Accountability through Patient Reported Outcomes .....	1
NQF Role in Promoting Accountability & Performance Improvement.....	2
PRO-PMs Applications: Benefits and Challenges.....	4
GUIDING PRINCIPLES .....	5
Psychometric Soundness .....	6
Person-Centered.....	6
Meaningful.....	7
Actionable.....	8
Implementable.....	8
PATHWAY FROM PRO TO NQF-ENDORSED PRO-PM .....	9
Pathway Section Related to the PRO.....	11
Pathway Section Related to the PROM.....	11
Pathway Section Related to the PRO-PM .....	12
Pathway Section Related to the NQF Endorsement Process.....	13
Alternate Pathway .....	14
KEY IMPLICATIONS AND RECOMMENDATIONS RELATED TO NQF CRITERIA.....	14
Overview .....	14
Evidence that the PRO is of Value to the Target Population .....	16
Evidence that the Measured PRO is Responsive to Intervention .....	16
Specification of the PRO-PM.....	18
Reliability and Validity of Both the PROM and the PRO-PM .....	18
Missing Data and Response Rates .....	20
Feasibility .....	20
Usability and Use .....	21
FUTURE DIRECTIONS.....	21
APPENDICES .....	25
Appendix A—Expert Panel Roster.....	25
Appendix B—Characteristics for Selecting PROMs.....	28
Appendix C—Glossary.....	32

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

1 **National Quality Forum**  
2 **Patient Reported Outcomes (PROs) in Performance Measurement**

3  
4 **INTRODUCTION**

5 **US Healthcare: Performance Improvement & Accountability**

6 Widespread variation in the quality of healthcare in the United States is well documented.<sup>1,2,3,4,5,6</sup>  
7 Although there are many laudable examples across the country where safe, effective, affordable care  
8 and support services are consistently provided serious gaps persist. Coupled with the need to constrain  
9 escalating healthcare costs—threatening the livelihoods of individuals and families and the overall  
10 national economy— intense focus is being placed on performance improvement and holding providers  
11 accountable to tackle the double edged sword of achieving the highest quality care at the lowest  
12 possible costs. The Affordable Care Act has several provisions targeting this challenge including the  
13 creation of a National Quality Strategy (NQS) to serve as a blueprint to *improve the delivery of health*  
14 *care services, patient health outcomes, and population health.*<sup>7</sup> Released in March 2011 and updated  
15 yearly, the NQS identifies three overarching aims of better care, healthy people and communities, and  
16 affordable care and six priority areas<sup>8</sup> for collective action to ultimately drive towards a high-value  
17 health system.<sup>9,10</sup>

18 **Achieving Performance Improvement & Accountability through Patient Reported Outcomes**

19 Patient and family engagement is increasingly acknowledged as a key component of a comprehensive  
20 strategy, including performance improvement and accountability, in achieving a high quality, affordable  
21 health system. Emerging evidence affirms patients who are engaged in their care tend to experience  
22 better outcomes<sup>11</sup> and choose less costly but effective interventions, such as physical therapy for low  
23 back pain, after undergoing a process of share decision-making.<sup>12</sup> Promising approaches to authentically  
24 involve patients and their families at multiple levels are being implemented across the country including  
25 serving on governance boards at hospitals and contributing to system and practice redesign to make  
26 care safer and more patient-centric.<sup>13,14</sup>

27 Historically, with the exception of collecting feedback on satisfaction or experience with care, patients  
28 remain an untapped resource in the assessment of the quality of care and that of long-term support  
29 services. Patients are a valuable and arguably the authoritative source of information on other  
30 outcomes beyond experience including: health-related quality of life, functional status, symptom and  
31 symptom burden, and health-related behaviors. For example, in the case of long- term support services  
32 for persons with disabilities, asking about valued outcomes such as increased communication and self  
33 help skills, and improved social interactions. Hence, it is critically important to engage patients by  
34 building capacity and infrastructure to routinely capture patient-reported outcomes and then use this  
35 data to develop performance measures to allow for accurate appraisals of quality and efficiency.

37 **NQF Role in Promoting Accountability & Performance Improvement**

38 Valid, reliable measures are foundational for evaluating and monitoring performance and fostering  
39 accountability. The National Quality Forum (NQF) is a voluntary consensus standard setting organization  
40 recognized under the National Technology Transfer and Advancement Act.<sup>15</sup> In this role NQF endorses  
41 performance measures as consensus standards to assess the quality of healthcare for use in  
42 accountability applications such as public reporting and payment as well as performance improvement.  
43 NQF is a neutral evaluator of performance measures but is not a measure developer. NQF convenes  
44 diverse stakeholders to evaluate measures based on the well-vetted criteria (available [here](#)).


45 The field of performance measurement is evolving to meet the demands of increased accountability to  
46 improve outcomes in both quality and costs. In tandem, the direction for NQF-endorsed performance  
47 measures includes:

- 48 • a drive toward higher performance reflected in more outcome measures rather than very basic  
49 processes such as assessment;
- 50 • measuring disparities;
- 51 • a shift toward composite measures that summarize multiple aspects of care;
- 52 • harmonization of measures across sites and providers; and
- 53 • measurement across longitudinal patient-focused episodes including outcome measures,  
54 process measures with direct evidence of impact on desired outcomes; appropriateness  
55 measures; and cost/resource use measures coupled with quality measures, including overuse.

57 Figure 1 depicts the relationship between structure, process, and outcome. For NQF endorsement, there  
58 is a hierarchical preference for performance measures of health outcomes that are linked to evidence-  
59 based processes or structures; or outcomes of substantial importance with a plausible link to healthcare  
60 processes. Next in the preferred hierarchy are measures of intermediate outcomes and processes  
61 closely linked to desired outcomes. Measures of processes that are distal to desired outcomes (e.g.,  
62 assess patient) and those that are satisfied by a “checkbox” are considered to have the least impact on  
63 the goal of improving healthcare and health.

64 Figure 1. Structure-Process-Outcome

65



66

67

68 **Patient-Reported Outcomes Tools & Performance Measures**

69 Patient-reported outcomes (PROs) are defined as “any report of the status of a patient’s (or person’s)  
70 health condition, health behavior, or experience with health care that comes directly from the patient,  
71 without interpretation of the patient’s response by a clinician or anyone else.”<sup>16</sup> PRO has become an  
72 international term of art; use of term “patient” is intended to be inclusive of all persons, including  
73 patients, families, caregivers, and consumers more broadly. It is intended as well to cover all persons  
74 receiving supportive services, such as those with disabilities. The domains of patient-reported outcomes  
75 include:

- 76 • Health-related quality of life including functional status;
- 77 • Symptoms and symptom burden;
- 78 • Experience with care; and
- 79 • Health-related behaviors.

80 Various tools (e.g., instruments, scales, single-item measures) that enable assessment of patient-  
81 reported health status for physical, mental, and social well-being are referred to as PRO measures  
82 (PROMs). To include patient-reported outcomes more systematically as an essential component of  
83 assessing the quality of care or services provided, and as part of accountability programs such a value-  
84 based purchasing or public reporting, distinguishing between PROMs (i.e., tools) and aggregate-level  
85 performance measures is important.

86 A PRO-based performance measure (or PRO-PM) is based on patient-reported outcome data  
87 aggregated for an entity deemed as accountable for the quality of care or services delivered. Such  
88 entities can include (but would not be limited to) supportive services providers, hospitals, physician  
89 practices, or accountable care organizations (ACOs). NQF endorses performance measures (PRO-PMs)  
90 for purposes of performance improvement and accountability; NQF does not endorse the tools to  
91 measure PROs (PROMs). Table 1 illustrates the distinctions among PRO, PROM, and PRO-PM. Full  
92 definitions are in the glossary ([Appendix C](#)).

93  
94  
95  
96  
97  
98  
99  
100

101 Table 1. Distinctions among PRO, PROM, and PRO-PM: Two Examples

<b>Target Population</b>	Patients with clinical depression	Persons with intellectual or developmental disabilities
<b>PRO</b> (concept)	Symptom: depression	Functional Status-Role: employment
<b>PROM</b> (instrument, tool, single-item measure)	PHQ-9 ©, a standardized <i>tool</i> to assess depression	Single-item measure on National Core Indicators Consumer Survey: <b>Do you have a job in the community?</b> <i>A community job refers to paid work - either competitive or supported employment (includes both individual and group employment, such as a work crew or enclave). It does not include work done in facility-based settings like sheltered workshops. It also does not include volunteer work.</i>
<b>PRO-PM</b> (PRO-based performance measure)	Percentage of patients with diagnosis of major depression or dysthymia and initial PHQ-9 score >9 with a follow-up PHQ-9 score <5 at 6 months (NQF #0711) and at 12 months (NQF #0710)	The proportion of people who have a job in the community

102

103 **PRO-PMs Applications: Benefits and Challenges**

104 Interest and appreciation of the value of using PROMs in performance measurement as part of the  
 105 broader accountability and performance improvement landscape is mounting. To accelerate the  
 106 adoption of PROMS to PRO-PMs that can be used for quality improvement and accountability two  
 107 challenges must be addressed. First, PROMs have not been widely adopted for clinical use outside  
 108 research settings in the United States and therefore may be unfamiliar to many health professionals,  
 109 payers, and provider institutions. Second, more research is needed on best practices for aggregating  
 110 patient data on PROMs to measure performance at multiple levels of analysis (e.g., individual, group  
 111 practice, organization).

112 Foundational work is needed to address these challenges. In response, NQF with funding from the  
 113 Department of Health and Human Services is conducting the *PROs in Performance Measurement*  
 114 project. The project goals are to:

- 115 • Identify key characteristics for selecting PROMs to be used in PRO-PMs;
- 116 • Identify any unique considerations for evaluating PRO-PMs for NQF endorsement and use in  
 117 accountability or performance improvement applications; and
- 118 • Lay out the pathway to move from PROMs to NQF-endorsed PRO-PMs.



119 This project is purposively designed to bring together stakeholders who could facilitate the groundwork  
120 for developing, testing, endorsing and implementing PRO-PMs. Those stakeholders included  
121 researchers, health professionals, performance measure developers, and consumer and purchaser  
122 representatives (see [Appendix A](#)). We convened two workshops with an expert panel and commissioned  
123 two papers to achieve the goals of the project and help accelerate progress. The papers focused on the  
124 methodological issues and served as background for the workshops – the first focused on selecting  
125 PROMs for use in performance measurement ([available here](#)) and the second on the reliability and  
126 validity of PRO-PMs ([available here](#)).

127 Encouraging, are the national and international examples on whose successful experiences we can build.  
128 At the workshop valuable insights were gleaned on approaches to data collection/aggregation and  
129 practical pointers around implementation (e.g., getting buy-in from providers). At the first workshop,  
130 colleagues from the Dartmouth Spine Institute and Massachusetts General Hospital presented on their  
131 experiences with using PROMs in patient care and performance improvement ([available here](#)). At the  
132 second workshop, representatives from the Centers for Medicare and Medicaid Services Health  
133 Outcomes Survey; England, and Sweden presented on their initiatives to publicly report PRO-PMs  
134 ([available here](#)). These discussions informed the recommendations found later in this report and the  
135 path forward. Additionally, there is also a large body of knowledge on using experience with care  
136 measures as PRO-PMS from which lessons can be learned (e.g., performance measures based on  
137 CAHPS).

138 This report captures the insights from this effort to date and provides recommendations to move the  
139 field of performance measurement forward. The remaining sections of this report cover: guiding  
140 principles, a detailed pathway from PROs to PRO-PMs, key implications and recommendations related to  
141 NQF endorsement criteria, and future directions.

142

## 143 **GUIDING PRINCIPLES**

144 During the first workshop the Expert Panel discussed key characteristics for identifying PROMs most  
145 suitable for developing and testing PRO-based performance measures (PRO-PMs). They conceptualize  
146 these ideas as “guiding principles” for using PROMs in the context of performance measurement: they  
147 are not NQF endorsement criteria per se, but served as foundational constructs for their  
148 recommendations on the pathway from PRO to PRO-PM and related NQF endorsement criteria. PROM  
149 developers and PRO-PM measure stewards should also take these into account in preparing submissions  
150 and documentation for NQF consideration for endorsement.

151 The guiding principles, described below, place the patient front and foremost— and serve as the  
152 underpinning of the thinking that shaped the pathway from PROs to PRO-PMs discussed in the next  
153 section of this report. The word “patient” is often used as shorthand to comprise patients, families,  
154 caregivers, and consumers more broadly. It warrants emphasizing that this term is meant to be inclusive  
155 of persons receiving supportive services, such as those with disabilities. With this in mind, moving

156 forward NQF must ensure that the emerging portfolio of PRO-PMs addresses a range of health care  
157 services that expand outside the walls of a particular clinical setting of care.

158 The five guiding principles encompass the following: meeting technical psychometric standards; being  
159 person-centered; having meaning to individuals responding to PROMs; being actionable; and being  
160 implementable.

### 161 **Psychometric Soundness**

162 Workshop participants agreed on several psychometric properties as a baseline set of requirements to  
163 be considered in selecting PROMs for use in PRO-PMs. These are delineated in Box 1 and are derived  
164 from the first commissioned paper. [Appendix B](#) provides the expanded explanations for these scientific  
165 properties of instruments or tools to measure them. The remaining three sets of principles below  
166 presume that the main elements of reliable, valid, responsive and feasible PROMs are adequately  
167 covered and demonstrated.

168 Box 1. Characteristics for Selecting PROMs Identified in Commissioned Paper

1. Conceptual and Measurement Model Documented
2. Reliability
  - 2a. *Internal consistency (multi-item scales)*
  - 2b. *Reproducibility (stability over time)*
3. Validity
  - 3a. *Content Validity*
  - 3b. *Construct and Criterion-related Validity*
  - 3c. *Responsiveness*
4. Interpretability of Scores
5. Burden
6. Alternatives modes and methods of administration
7. Cultural and language adaptations
8. Electronic health record (EHR) capability

169

### 170 **Person-Centered**

171 Resoundingly, “person-centeredness” was the overarching theme that arose from the workshop  
172 discussions. In this context, using PROMs is viewed as an important step towards engaging patients,  
173 health professionals and other entities in creating a person-centered health system. The workshop  
174 participants also identified the opportunity for PROMs to facilitate shared decision-making (SDM),  
175 another strategy for engaging patients. SDM is defined as *a collaborative process that allows patients  
176 and their providers to make health care decisions together, taking into account the best scientific  
177 evidence available, as well as the patient’s values and preferences.*<sup>17</sup> For SDM, clinicians and other health  
178 care staff can use the instrument, scale, or single-item measure (PROM) to engage patients in their own  
179 preferred self-management and goal attainment by identifying outcomes important to them and  
180 tracking change over time. An important caveat to this discussion is not all patients want to engage in

181 formal SDM activities. Therefore, although contributing to SDM efforts is desirable, not all PROMs need  
182 to enable SDM.

183 Importantly, as a final consideration of person-centeredness, as patients become more engaged in their  
184 care by providing systematic feedback on outcomes such as their functional or health status, the flow of  
185 information between clinicians and patients must be bi-directional. This may mean that health  
186 professionals interpret PROM information back to their patients; it may mean that mechanisms are  
187 established to give patients their own information directly (displayed in easy-to-understand ways). With  
188 steps such as these, respondents to PROMs can benefit from seeing results in a timely way, and this type  
189 of service can balance any perceived burdens they may feel about completing data-collection activities.  
190 Although these considerations may not affect NQF endorsement efforts directly, the Expert Panel  
191 wished to emphasize that having PRO-PMs that can be used in this manner is desirable.

## 192 **Meaningful**

193 Closely intertwined with person-centeredness is the concept of “meaningfulness.” Meaningfulness  
194 encompasses the relevance and degree of importance of the concepts measured by the PROM from the  
195 perspective of patients, their families, and caregivers—as well as clinicians and other health  
196 professionals who serve them. Among the concepts that PROMs would ideally capture are the following:  
197 the impact of health-related quality of life (including functional status); symptom and symptom burden;  
198 experience with care and satisfaction with the services; perceived utility of the services for achieving  
199 personal goals; or health-related behaviors. As suggested above, the focus comprises both “traditional”  
200 health care services broadly defined and supportive services for persons with disabilities.

201 Workshop participants debated how best to demonstrate evidence that stakeholders think a particular  
202 PROM is meaningful. The following framework, coined as the three “Cs”, can serve as a starting point for  
203 thinking about how to operationalize the construct of being meaningful:

- 204 • Conceptual – the first step is to engage people in the dialogue of what matters most to them to  
205 define the concepts to be covered within PROs.
- 206 • Contextual – the second step is to learn how individuals use the information derived from either  
207 a PROM or a PRO-PM. Individuals here are defined very broadly to include not just “patients”  
208 (however construed for the application at hand) but also clinicians, other health professionals,  
209 administrators, and perhaps even policymakers. For example, does such information facilitate  
210 their participation managing their own health care? Does it help people to select a high- quality  
211 provider of health or supportive services? Does such data contribute to the discourse on larger  
212 social issues such as achieving high- quality care at acceptable costs?
- 213 • Consequential – the third step is determining what happens when the information (from a PRO-  
214 PM) is used in accountability programs (e.g., value-based purchasing) or performance  
215 improvement to assess and assure the availability of high quality of care and impact on  
216 availability of services. This step also needs to consider if the PRO-PM is consequential to the  
217 individual or family member.

218

219 **Actionable**

220 Actionability refers to evidence that the outcome of interest (i.e., PRO) is responsive to a specific health  
221 service or intervention. The guiding principle of “actionability” is that performance measures (i.e., PRO-  
222 PMs) intended for both accountability and improvement should be supported by evidence that the  
223 health care providers being measured can influence the person’s short- or long-term outcomes. The  
224 position held by the majority of workshop participants was that without such evidence, a PRO-PM is not  
225 a valid indicator of quality.

226 From the workshop discussions emerged a spectrum of actionability for identifying the highest leverage  
227 PROs to accelerate on the path to PRO-PMs. This continuum had three levels:

- 228 • Highly actionable: evidence that the PRO is responsive to intervention as demonstrated in  
229 clinical studies and the intervention has been implemented in practice. Initial efforts for  
230 developing PRO-PMs should be focused here.
- 231 • Moderately actionable: evidence of responsiveness to intervention in clinical studies but there is  
232 limited experience with the intervention in practice. Moderately actionable PROs can be used  
233 for accountability but with caution. This is the next tier for consideration of accountability and  
234 performance measurement.
- 235 • Weakly or not actionable: evidence of responsiveness to intervention is weak in clinical studies  
236 and the intervention has not been implemented in practice. These PROs should not be  
237 considered for accountability or performance improvement purposes at this time (and thus not  
238 for NQF endorsement of PRO-PMs).

239 Some workshop participants offered a counter argument to the idea that all PROs considered for  
240 purpose of accountability or performance measurement must be actionable. The rationale presented  
241 was some outcomes are worth measuring even though they may not be amenable to change by  
242 providers—but are used by patients and clinicians to make informed decisions. Although not resolved at  
243 the workshop this is worthy of further exploration.

244 **Implementable**

245 The guiding principle that a PROM should be “implementable” acknowledges that many diverse factors  
246 affect implementation. Most of these factors relate to barriers to adopting such tools (PROMs) or  
247 collecting data and reporting on PRO-PMs in many practices, institutions or other settings. There were  
248 many implementation issues raised during the workshop discussions. Although not exhaustive, the  
249 workshop participants emphasized the following list: administering PROMs in real-world situations;  
250 addressing literacy and health literacy of respondents; addressing cultural competency of clinicians and  
251 other service providers; dealing with the potential for unintended consequences related to patient  
252 selection; covering costs associated with using PROMS (especially those not available in the public  
253 domain); and adapting PROMs to computer-based platforms or other alternate formats.

254  
255

256 **PATHWAY FROM PRO TO NQF-ENDORSED PRO-PM**


257 The pathway displayed in [Figure 2](#), and described in detail below, lays out the critical steps in developing  
258 a PRO-based performance measure suitable for endorsement by NQF. It begins with the conceptual  
259 basis for identifying a PRO for performance measurement and proceeds through selecting a PROM and  
260 developing and testing a performance measure to achieving NQF-endorsement of a PRO-PM and using  
261 the performance measure for accountability and performance improvement. This pathway does not  
262 replace the existing NQF measure evaluation criteria, but rather describes how a PROM may form the  
263 basis of a PRO-PM that could be eventually endorsed by NQF. The existing NQF criteria *are* applicable to  
264 PRO-PMs, as well as the PROM used in the performance measure. Some recommendations for minor  
265 modifications to the NQF endorsement criteria to address the unique considerations of PRO-PMs are  
266 discussed in the next section.

267 Although NQF involvement occurs in the last section of the pathway, the earlier steps have implications  
268 for whether a performance measure will be suitable for NQF endorsement and are intended to serve as  
269 a guide and best practices to help ensure that PRO-PMs will meet NQF criteria. For example, steps 1 and  
270 2 in the pathway indicate that patients (broadly defined as above) should be involved in identifying  
271 quality issues and outcomes that are meaningful to those receiving the care and supportive services. If  
272 patients are involved at those steps, then developers will have amassed the information needed to  
273 demonstrate that the outcome is of value to patients . In the context of using this pathway leading to an  
274 NQF-endorsed performance measure, step 2 also suggests identifying outcomes with evidence that the  
275 outcome is responsive to intervention.

276 Our first recommendation is stated in the box below. The steps shown in Figure 2 and described below  
277 are intended to help ensure that a proposed performance measure will meet NQF criteria for  
278 endorsement.

**Recommendation 1.**

Those developing PRO-PMs to be considered for NQF endorsement should follow the basic steps shown in the pathway in Figure 2. Doing so will help ensure that the eventual PRO-PM and its supporting documentation conform to NQF endorsement criteria.



280 **Pathway Section Related to the PRO**

281 The pathway begins with the conceptual basis for identifying a PRO for performance measurement.

282 *1. Identify the quality performance issue or problem.*

283 Before resources are devoted to performance measurement, a clear understanding of the quality  
284 performance issue or problem related to healthcare or supportive services for a target population will  
285 direct the focus and establish the need for a performance measure. Input from all stakeholders including  
286 the recipients of the care and services, providers whose performance will be measured, payers,  
287 purchasers, and policy makers are critical to identifying priorities for performance measurement.

288 *2. Identify outcomes that are meaningful to the target population and are actionable by providers of*  
289 *care and services.*

290 After identifying the quality performance issue, the specific outcomes that are valued and meaningful to  
291 the target population should be identified. That is, the people receiving the healthcare or supportive  
292 services should be asked for their input. At this stage, all relevant desired outcomes should be identified  
293 even if they might not be assessed through patient-reported data.

294 As discussed previously, the Expert Panel suggested focusing performance measures on outcomes that  
295 are actionable, i.e., responsive to intervention by healthcare and service providers. Therefore, outcomes  
296 with evidence that they are influenced by at least one structure, process, intervention, or service should  
297 be identified.

298 *3. Determine whether patient-/person-reported information is the best way to assess the outcome of*  
299 *interest.*

300 Patient-/person-reported data is not necessarily the best way to assess every desired outcome identified  
301 in the prior step. The domains of health-related quality of life including functional status, symptoms and  
302 symptom burden, and health-related behaviors have been identified as outcomes for which individuals  
303 receiving healthcare and services may be the best or only source of information. However, other  
304 meaningful outcomes such as survival/mortality and hospital readmission could be assessed using  
305 another data source.

306 **Pathway Section Related to the PROM**

307 After the PRO of interest is identified, the pathway addresses the steps to select a PROM suitable to use  
308 in a performance measure.

309 *4. Identify existing PROMs for measuring the outcome (PRO) in the target population of interest.*

310 Many PROMs already exist and should be searched to identify any that measure the outcome of interest  
311 in the target population. PROMs that were developed years ago may not have benefited from patient  
312 input; therefore, it is important to include patients in selecting PROMs

313 *5. Select PROM suitable for use in performance measurement.*

314 The scientific (psychometric) characteristics that should be used in selecting a PROM for performance  
315 measurement were summarized above and appear in detail in [Appendix B](#). Of great importance is that  
316 PROMs be reliable, valid, and responsive in the target population. If there isn't an existing PROM for the  
317 target population suitable for use in a performance measure, then another existing PROM must be  
318 tested in the target population or a new PROM developed and tested before a performance measure  
319 can be developed. The commissioned paper on methodological issues related to PROMs provides a  
320 resource on considerations for selecting the PROM ([available here](#)).

321 *6. Use the PROM in the real world with the intended target population and setting.*

322 The Expert Panel agreed that PROMs should be used with the target population and in the settings for  
323 which performance measures are proposed before a PRO-PM is developed. Many PROMs were  
324 developed for research studies. This real-world application will identify feasibility issues related to  
325 administration, data capture, and workflow to use the PROM to assess individuals' responses to health  
326 care or supportive services intervention, provide feedback for self-management, and (as desired)  
327 facilitate shared decisionmaking.

328 Actual use of the PROM also generates the data needed to develop and test a PRO-PM for reliability and  
329 validity. The PROM could be used in a pilot or through more broad-based adoption. This step does not  
330 require an endorsed performance measure focused on administering the PROM. However, in some  
331 circumstances, adding steps for such a process measure may be considered and is discussed after the  
332 main pathway.

### 333 **Pathway Section Related to the PRO-PM**

334 After the PROM is selected and used in practice and sufficient data are available for testing, the pathway  
335 addresses specifying and testing a PRO-PM.

336 *7. Specify the outcome performance measure (PRO-PM).*

337 Developers specify how the outcome performance measure will be constructed. The metrics may be,  
338 for instance, an average change; percentage of patients improved; percentage of respondents meeting a  
339 specific benchmark value. The performance measure needs to be fully specified including the specific  
340 PROM, administration, and scoring; the target population and any exclusions; time frames for PROM  
341 administration as well as performance measurement; and risk adjustment.

342 *8. Test the PRO-PM for reliability, validity, and threats to validity.*

343 Developers need to test the performance measure for reliability and validity. They explicitly need to  
344 address a variety of threats to validity or other technical issues; these include the need for risk  
345 adjustment or stratification and options for doing this; appropriateness of potential exclusions; and  
346 options for dealing with missing data. A further challenge is explaining the level of equivalence of  
347 results when multiple PROMs are used.

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET



348 Testing of the PRO-PM is distinct from testing the PROM. Using a PROM with sound psychometric  
349 properties is necessary but not sufficient to assure a reliable and valid PRO-PM. The commissioned  
350 paper on methodological issues for PRO-PMs provides a resource on considerations and approaches to  
351 reliability and validity of the performance measure ([available here](#)).

## 352 **Pathway Section Related to the NQF Endorsement Process**

353 The last section of the pathway focuses on the NQF endorsement process.

354 *9. Submit the PRO-PM to NQF for consideration of NQF endorsement.*

355 The NQF endorsement process begins when developers submit a measure to NQF for consideration.  
356 Developers submit required information in NQF's standard form so that all the information needed to  
357 evaluate the measure is available to reviewers.

358 *10. Evaluate the PRO-PM against the [NQF Endorsement Criteria](#).*

359 NQF evaluates measures against four main endorsement criteria listed here and described and discussed  
360 in more detail below.

- 361 1. Importance to Measure and Report
- 362 2. Scientific Acceptability of Measure Properties
- 363 3. Feasibility
- 364 4. Usability and Use

365 In addition, NQF has criteria and processes to address measure harmonization and selection of the best  
366 measure form among competing measures, which also would apply to PRO-PMs.

367 *11. Use the endorsed PRO-PM for accountability and improvement.*

368 Once endorsed, NQF expects the measure to be used for accountability and performance improvement  
369 applications. Implementation of the performance measure facilitates improvement and measuring and  
370 tracking improvements. Use of the performance measure provides data on performance and  
371 improvement.

372 *12. Evaluate whether the PRO-PM continues to meet [NQF Criteria](#) to maintain endorsement.*

373 NQF reviews endorsed measures every three years to evaluate whether it continues to meet NQF  
374 criteria. In making its decision at this stage, NQF evaluates the measure on all criteria and considers  
375 information on actual use, improvement, and unintended adverse consequences. This information and  
376 results of the NQF endorsement maintenance decision also provide feedback to the beginning of the  
377 pathway and considerations for performance measurement.

378

379

## 380 **Alternate Pathway**

381 The main pathway depicted in Figure 2 and discussed above focuses on moving from a PRO to a PRO-PM  
382 – with the core construct an outcome that is meaningful to patients (broadly defined) and measured by  
383 a PROM that meets other desirable characteristics discussed in the guiding principles above. However,  
384 in some circumstances beginning to measure performance related to the administration and data  
385 capture of the PROM itself may be considered before moving straight to using the PRO data themselves.  
386 Ultimately, however, the goal is for outcome performance measures.

387 The primary purpose of a process performance measure focused on administration is to facilitate use of  
388 the PROM as described in step 6 of the main pathway and prepare the field for outcome performance  
389 measurement. Another potential reason for a process performance measure is concern that although  
390 the PRO is valued, it is not currently thought to be influenced by health care – but could be in the future.  
391 However, in this case, the PRO may not be a priority for performance measurement as indicated in step  
392 2.

393 The alternate pathway entails developing, testing, endorsing, and implementing such a process measure  
394 before developing the outcome measure; therefore, it has implications for time and resources. Some  
395 questions to consider before pursuing the additional steps related to a process performance measure  
396 include:

- 397 • *Is there another mechanism in place to facilitate use of a PROM?* If use of a PROM is achieved  
398 through other requirements such as regulations or accreditation, or accepted guidelines then a  
399 performance measure may not appreciably impact the extent of use.
- 400 • *Will the process performance measure result in having the data needed to develop and test an*  
401 *outcome performance measure?* The process performance measure should be specified so that it  
402 requires that a specific PROM is administered at designated intervals, with recording of the PROM  
403 value in the health record — not merely checking that it was administered. Alternatively a more  
404 substantive process measure focused on an evidence-based intervention in response to a specific  
405 value of a PROM could be constructed so that use of the PROM is required.
- 406 • *Is there a credible plan to implement the process performance measure and collect data?* If the  
407 process performance measure is not implemented so that providers are accountable for  
408 performance on using the PROM and capturing PROM data, it less likely to affect adoption of the  
409 PROM and advance development of an outcome measure.

410

## 411 **KEY IMPLICATIONS AND RECOMMENDATIONS RELATED TO NQF CRITERIA**

### 412 **Overview**

413 The [NQF endorsement criteria](#) and guidance on evaluating all performance measures also apply to PRO-  
414 based performance measures (PRO-PMs). The four main endorsement criteria were mentioned  
415 previously (importance to measure and report, scientific acceptability of measure properties, feasibility,  
416 and usability and use). NQF committee members use the criteria to evaluate measures submitted for

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

417 potential endorsement. When these criteria are met and measures are endorsed they are considered  
 418 suitable for accountability and performance improvement. Potential submitters (i.e., developers) also  
 419 need to be very familiar with the NQF criteria so as to be able assemble the required documentation as  
 420 part of their submission.

421 PRO-PMs may, however, have some special or even unique aspects that warrant special consideration.  
 422 Table 2 lists these factors, in the context of the main NQF endorsement criteria. The left column  
 423 provides an abbreviated description of the criteria. The middle column identifies special considerations  
 424 for evaluating PRO-PMS, but they are not unique to PRO-PMs. Several unique aspects about PRO-PMs  
 425 are identified in the right column and may warrant some modifications to the NQF criteria to ensure  
 426 they are suitable for endorsement. This section provides recommendations and rationales for modifying  
 427 the NQF criteria or guidance.

428 Table 2. NQF Endorsement Criteria and Special Considerations Related to PRO-PMs

<b>Abbreviated <a href="#">NQF Endorsement Criteria</a></b>	<b>Special Considerations For Evaluating PRO-PMs that are relevant to other performance measures</b>	<b>Unique Considerations for Evaluating PRO-PMs</b>
<b>Importance to Measure and Report</b> a. High impact b. Opportunity for improvement c. Health outcome OR evidence-based process/structure of care		<ul style="list-style-type: none"> <li>• Patient/person must be involved in identifying PROs for performance measurement (person-centered; meaningful).</li> <li>• Evidence supports that the PRO is responsive to intervention (actionable).</li> </ul>
<b>Scientific Acceptability of Measure Properties</b> a. Reliability <ol style="list-style-type: none"> <li>1. precise specifications</li> <li>2. reliability testing for either data elements or performance measure score</li> </ol> b. Validity <ol style="list-style-type: none"> <li>1. specifications consistent with evidence</li> <li>2. validity testing for either data elements or performance measure score</li> <li>3. exclusions</li> <li>4. risk adjustment</li> <li>5. identify differences in performance</li> <li>6. comparability of</li> </ol>	<ul style="list-style-type: none"> <li>• Data collection instruments/tools should be identified (e.g., specific PROM instrument, scale or single-item)</li> <li>• If multiple data sources (i.e., PROMs, methods, modes, languages) comparability/equivalency of performance scores should be demonstrated.</li> </ul>	<ul style="list-style-type: none"> <li>• Specifications should include standard methods, modes, languages of administration; whether (and how) proxy responses are allowed; standard sampling procedures; the handling of missing data; and calculation of response rates to be reported with the performance measure results.</li> <li>• Reliability and validity should be demonstrated for <u>both</u> the data (PROM) and the PRO-PM performance measure score.</li> <li>• Response rates can affect validity and should be addressed in testing.</li> <li>• Differences in individuals' PROM values related to PROM instruments or methods,</li> </ul>

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

Abbreviated <a href="#">NQF Endorsement Criteria</a>	Special Considerations For Evaluating PRO-PMs that are relevant to other performance measures	Unique Considerations for Evaluating PRO-PMs
multiple data sources		modes, and languages of administration need to be analyzed and potentially included in risk adjustment.
<b>Feasibility</b> a. Data generated and used in care delivery b. Electronic data c. Data collection strategy can be implemented	<ul style="list-style-type: none"> <li>The burden of data collection, including those related to use of proprietary PROMs, are minimized and do not outweigh the benefit of performance measurement.</li> </ul>	<ul style="list-style-type: none"> <li>The burden to respondents (people providing the PROM data) should be minimized (e.g., availability/accessibility enhanced by multiple languages, methods, modes).</li> <li>Infrastructure to collect PROM data and integrate into workflow.</li> </ul>
<b>Usability and Use</b> a. Accountability and transparency b. Improvement c. Benefits outweigh unintended negative consequences	<ul style="list-style-type: none"> <li>Adequate demonstration of the criteria specified above supports usability and ultimately the use of PRO-PM for accountability and performance improvement.</li> </ul>	

429

430 **Evidence that the PRO is of Value to the Target Population**

**Recommendation 2.**

The NQF criterion or guidance for importance to measure and report should require evidence that the target population values the measured PRO and finds it meaningful.

431

432 Person-centeredness is a key principle for developing PRO-PMs. As shown in Figure 2, identifying  
 433 outcomes of value to the target population is a critical early step in the pathway to endorsement of a  
 434 PRO-PM. NQF’s current criteria require evidence that the measured aspect of care is of value to the  
 435 patient for measures of experience with care. Experience with care is considered one type of patient-  
 436 reported outcome; therefore, the requirement for having evidence of the value to the patient can be  
 437 expanded to apply to all patient-reported outcomes.

438 **Evidence that the Measured PRO is Responsive to Intervention**

**Recommendations 3-5.**

3. The NQF criterion regarding evidence should require identification of the causal pathway linking the PRO and healthcare structures, processes, interventions, or services (i.e., process –PRO).

4. NQF should apply the existing criterion and guidance regarding evidence for a process performance measure to PRO-PMs – i.e., *a systematic assessment and grading of the quantity, quality, and*

*consistency of the body of empirical evidence* that at least one of the identified health care structures, processes, interventions, or services influences the PRO.

5. NQF should consider adopting this approach for all health outcome performance measures regardless of whether the data are self-reported by patients (or acceptable proxy respondents) or by clinicians.

439

440 Actionability was a key principle identified for developing PRO-PMs. The Expert Panel suggested that  
441 evidence that the PRO is responsive to intervention be required for NQF endorsement of a PRO-PM. This  
442 represents a departure from NQF's current NQF guidance regarding evidence for performance measures  
443 of health outcomes.

444 For health outcome measures, NQF requires only a rationale linking the outcome to at least one health  
445 care structure, process, intervention, or service; it does not require submitting and evaluating  
446 information on systematic reviews of the empirical body of evidence as required for other types of  
447 performance measures. NQF's position on evidence for health outcomes is based on the following  
448 reasoning:

- 449 • Health outcomes such as survival, physical or cognitive function, relief of symptoms, or  
450 prevention of morbidity are the reasons for seeking care and the goal of providing care.  
451 Therefore, these outcomes are central to measuring the performance of those rendering health  
452 care or supportive services.
- 453 • Health outcomes are often integrative. As such, they may reflect the influence of multiple  
454 clinicians and care processes and therefore are based on multiple bodies of evidence.  
455 Submitting information on multiple bodies of evidence could be burdensome and a disincentive  
456 for submitting outcome performance measures for NQF endorsement.
- 457 • Measuring health outcomes to identify variability in performance is a key driver to identifying  
458 strategies for improvement, even for outcomes previously thought to not be modifiable such as  
459 central line-associated bloodstream infections.

460 The current environment in which penalties may be associated with performance measure scores, has  
461 increased concern about using outcome performance measures for accountability. To mitigate that  
462 concern to some extent, the Expert Panel suggested focusing performance measurement on PROs that  
463 are meaningful to patients *and* with evidence that they are responsive to intervention. England and  
464 Sweden are leaders in the area of measuring PROs for performance measurement and appear to have  
465 taken this approach. England measures and reports performance PROMs focused on specific surgical  
466 procedures to ameliorate problems with function and symptoms-hip and knee replacement and varicose  
467 vein surgery ([access reports here](#)). Sweden measures and reports performance on PROMs related to  
468 surgical procedure outcomes and complications ([access report here](#)). Sweden also reports performance  
469 on PROMs for a few medical conditions such as function 3 months after stroke and improvement after  
470 initiation of biological drug therapy for rheumatoid arthritis.

471 The Expert Panel acknowledged the trade-offs to a condition-specific approach. First, it does not include  
472 much of the population receiving healthcare and supportive services. Second, even for a specific

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

473 condition, limiting performance measurement to those who received only one possible intervention  
474 (i.e., surgery) does not provide a complete picture on performance related to the condition. A related  
475 question is whether to measure the PRO with generic or condition-specific PROMs. Condition-specific  
476 PROMs may be more responsive to change. However, generic measures offer more breadth, which is  
477 relevant given that many patients have more than one condition. Using both generic and condition-  
478 specific PROMs affords the opportunity to better understand the benefits and drawbacks of both. These  
479 issues will need to be considered and revisited as we gain experience with PRO-PMs.

#### 480 **Specification of the PRO-PM**

##### **Recommendation 6.**

NQF should require measure specifications for PRO-PMs that include the specific PROM(s); standard methods, modes, and languages of administration; whether (and how) proxy responses are allowed; standard sampling procedures; the handling of missing data; and calculation of response rates to be reported with the performance measure results.

481

482 Performance measures used in accountability applications must be standardized. Therefore, developers  
483 must specify them in ways to ensure consistent implementation across providers. No unlike other  
484 performance measures, specifications should identify the data collection tool – i.e., the specific PROM(s)  
485 used to obtain the data for each patient (respondent). Specifications that are unique to PRO-PMs  
486 include standard methods, modes, and languages of administration; whether (and how) proxy responses  
487 are allowed; standard sampling procedures; the handling of missing data; and calculation of response  
488 rates to be reported with the performance measure results.

#### 489 **Reliability and Validity of Both the PROM and the PRO-PM**

##### **Recommendations 7-8.**

**7.** NQF should require testing for PRO-PMs that demonstrates the reliability of both the underlying PROM in the target population and the performance measure score must be demonstrated.

**8.** NQF should require testing for PRO-PMs that demonstrate the validity of both the underlying PROM in the target population and the performance measure score. Empirical validity testing of the performance measure is preferred.

If empirical validity testing of the performance measure is not possible, a systematic assessment of face validity should be accomplished with experts other than those who created the measure, including patients reporting on the PROM; and specifically addresses the approach to aggregating the individual PROM values.

490  
491 As already noted, NQF endorses performance measures; it does not endorse instruments or scales (i.e.,  
492 the PROM). However, the PROM values are the data used in the performance measure, so the  
493 psychometric soundness of the PROMs specified for use in the performance measures is crucial to the  
494 reliability and validity of the PRO-PM. The Expert Panel agreed that reliability and validity of the PROM is  
495 necessary but not sufficient to ensure reliability and validity of the PRO-PM; therefore it recommended  
496 that testing for both the PROM and the PRO-PM are needed. Approaches to reliability and validity

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

497 testing, risk adjustment, and analyses of potential threats to validity were discussed in a commissioned  
498 paper on methodological issues related to PRO-PMs. ([available here](#))

499 NQF criteria currently allow for testing reliability and validity for either the critical data elements used in  
500 the performance measure or for the computed performance measure score. In the case of the PRO-PM,  
501 a critical data element is the PROM value.

502 PROMs have traditionally been developed for group comparisons in research rather than for decisions  
503 about individual patients or service recipients. In a research context, investigators usually assign subjects  
504 randomly to treatment and control groups; whereas patients are not randomly assigned to provider of  
505 healthcare and support services. The primary question is whether demonstrated reliability and validity  
506 of the PROM is sufficient in itself to assume reliability and validity of the performance measure. NQF can  
507 consider two approaches to deal with this issue.

508 1. Accept reliability and validity of the PROM in the target population as meeting NQF criteria for  
509 reliability and validity testing at the data element level as long as the additional issues related to  
510 threats to validity are tested and analyzed for the performance measure score (i.e., exclusions,  
511 risk adjustment, discriminating performance comparability if multiple PROMs are used).

512 2. Require reliability and validity testing of the computed performance measure score *in*  
513 *addition to* providing evidence of reliability and validity of the PROM in the target population.  
514 The related threats to validity must also be addressed (i.e., exclusions, risk adjustment,  
515 discriminating performance comparability if multiple PROMs are used).

516 The primary advantage of the first approach is that measure developers can expend fewer resources for  
517 measure testing. The primary disadvantage of the first approach is less confidence in the results of the  
518 performance measure. The advantages and disadvantages of the second approach are the opposite.

519 The Expert Panel agreed that the second approach is most appropriate in the context of performance  
520 measures endorsed by NQF for accountability and performance improvement. Further, the impact on  
521 resources for testing is not substantial, given the need to develop and test risk adjustment with either  
522 approach.

523 The data needed for the required testing and analysis related to the threats to validity (e.g.,  
524 development and testing of risk adjustment and analysis of comparability if specified with multiple  
525 PROMs) could also be used to conduct reliability testing of the performance measure such as a signal-to-  
526 noise analysis. Therefore, a requirement for reliability testing of the performance measure would not  
527 present an undue burden.

528 Validity testing of the performance measure score would require additional data to test hypothesized  
529 relationships such as data on another performance measure or information to compare groups known  
530 to differ on quality. NQF criteria currently allow a systematic assessment of face validity of the  
531 performance measure score as an indicator of quality. Because there are a variety of ways that the  
532 individual values on the PROM could be aggregated, there could be differences in the validity of the

533 results for indicating quality. Ideally, empirical validity testing would be conducted. If that is not  
534 possible, then face validity should be evaluated systematically with experts, including patients reporting  
535 on the PROM other than those who created the measure.

#### 536 **Missing Data and Response Rates**

##### **Recommendations 9.**

NQF should require analysis of missing data and response rates to demonstrate they do not bias the performance measure results

537

538 Missing data is an important consideration when using PROM data for performance measurement. This  
539 issue encompasses missing responses on a multi-item scale; missing responses from eligible patients and  
540 its impact on potential response bias; missing information due to exclusions; and using proxies in the  
541 face of missing responses. Systematic missing data affects validity. Processes must be in place to  
542 safeguard against these exclusions and biases, and more robust engagement strategies are needed over  
543 time to prevent these gaps in response rates. NQF criteria for validity currently address exclusions and  
544 missing data is often an explicit or implicit exclusion. Because missing data is likely to be more prevalent  
545 with PRO-PMs it should be addressed explicitly in measure specifications as identified above and in  
546 analysis and evaluation of the PRO-PM.

#### 547 **Feasibility**

##### **Recommendation 10.**

NQF's feasibility criterion should consider both individuals providing PROM data (patients, service recipients, respondents) and the providers whose performance is being measured.

548

549 The general principles of feasibility for a performance measure apply to PRO-PMs. Burden of data  
550 collection usually applies to the healthcare or service provider whose performance is being measured;  
551 however, the unique issue that needs to be considered with PRO-PMs is the potential burden to the  
552 individuals who are providing the PROM data. Burdens to both individuals and the providers delivering  
553 health or support services will influence response rates, missing data, and ultimately the reliability and  
554 validity of a performance measure. Flexibility to decrease burden such as collecting PROM data through  
555 tools developed in multiple languages and applying different methods, and modes of administration is  
556 desirable.

557 As with all performance measures, data collection and reporting for PRO-PMs may present a variety of  
558 costs to the providers whose performance is being measured. Such costs may involve expenditures on  
559 infrastructure such as computers and programming and in some cases, the need to pay licensing or  
560 other fees for proprietary instruments or measures. A potential difference between PRO-PMs and other  
561 performance measures regarding infrastructure is that currently PROMs are not widely in use and an  
562 information technology infrastructure is less advanced than electronic health records.



563 When considering burdens, it is important to weigh them against benefits. Obtaining PROM data is not  
564 merely a process to collect data for performance measurement; rather the PROM is used to assess  
565 patient status or response to intervention; provide feedback for self-management; and engage patients  
566 in shared decisionmaking (as desired). The benefits of performance measurement and reporting are  
567 widely accepted. As with other performance measures, the burden of data collection does not stop  
568 performance measurement; rather, it should serve as an impetus to find more efficient ways to collect  
569 PROM data and to use resources for performance measurement on PRO-PMs that meet NQF criteria.

#### 570 **Usability and Use**

571 As with any NQF-endorsed measure, an NQF-endorsed PRO-PM is intended for use in both  
572 accountability and improvement applications. The primary factors of whether a performance measure is  
573 usable are whether it is in use and is making a difference. At the time of initial NQF endorsement, of  
574 course, usability may be only theoretical. The performance measure may have a rationale and plans for  
575 use in accountability and improvement activities. On subsequent review for endorsement maintenance,  
576 however, NQF requires information on use and data on improvement. NQF also requests public  
577 comment on experiences with using the performance measure.

578

#### 579 **FUTURE DIRECTIONS**

580 This project provided a forum for dialogue across numerous stakeholders to address difficult conceptual  
581 and methodological issues. The aim was to hasten the endorsement and ultimately the implementation  
582 of PRO-based performance measures for use in accountability programs and performance improvement  
583 initiatives. The guiding principles articulated above and the detailed pathway (Figure 2) of taking a PRO  
584 to PRO-PM are intended to steer work in the field in ways to ensure a more person-centered approach.  
585 This report begins to lay a roadmap to get us there.

586 Nevertheless, some pressing methods issues require further examination. The examples given here are  
587 high-priority needs to fill. First, identifying and evaluating best practices for using proxy respondents are  
588 important next steps; the goal is not to exclude from our assessments various disadvantaged  
589 populations, such as frail elders or children, who may be unable to respond to PROMs on their own.  
590 Second, PROs may be evaluated through different PROMs (tools); demonstrating the equivalency of the  
591 data from different PROMs warrants careful attention. Of particular concern is the trade-off between  
592 allowing implementers as much flexibility as possible without sacrificing validity and the ability to do  
593 meaningful comparisons. Third, viable solutions are needed to overcome barriers to calibrating multiple  
594 individual-level PROMs (i.e., “disparate” data sources) to a standard scale. Finally, some considerations  
595 will arise as use of PROMs and PRO-PMs expands and evolves. These include the advisability and utility  
596 of calculating composite endpoints or combining PRO-PMs salient to a particular domain such as health  
597 related quality of life or health related behaviors. Having such a broad picture of the outcomes reflected  
598 in the PRO-PMs strongly appeals to consumers who want a complete picture of health and well-being.

599 Using information technology to enable the widespread collection and use of PRO-based performance  
600 measures requires further exploration to capitalize fully on existing and future infrastructure.  
601 Technology can increase response rates by allowing individuals or their proxy respondents to provide  
602 responses from home or elsewhere via telephone, computer tablet or through web-based PRO  
603 measurement systems. Technology permits scanning of paper and pencil responses and it allows for  
604 quick scoring and giving feedback to respondents. Computers are an essential technology for real-time  
605 application of item response theory in computer adaptive testing, which allows more efficient  
606 administration of PROMs and calibration of multiple instruments to a standard scale.

607 Integrating PROMs into electronic health records (EHRs) can facilitate their use for patient-centered care  
608 management and also provide data for performance improvement, but implementers must take  
609 account of several factors. Data standards are needed before PROM data can be fully incorporated into  
610 EHRs. Formulating such standards requires making decisions about aspects of capturing PROM data such  
611 as the following: source of the information (e.g., self or proxy); specific PROM instrument; method and  
612 mode of data collection; PROM value or response; and dates on which information was captured and  
613 scores were computed. In addition, how PROM data might be used in clinical practice needs to be  
614 clearly specified. These features include how to best display results, and when and how alerts should  
615 appear.

616 Incorporating data provided by patients into the health record may increase their sense of ownership of  
617 the record; doing so may also raise demands for extracting information and for providing data. This is an  
618 opportune time to include PROMs in EHRs and leverage the resources being directed to adoption of  
619 EHRs through the [Medicare EHR Incentive Program](#) referred to as “Meaningful Use.” Nevertheless,  
620 some PROMs, such as those focused on people’s experience with care, may not be appropriate to  
621 include in EHRs because current tools and approaches are based on the premise of anonymity.

622 In closing, the path forward toward NQF endorsement of PRO-based performance measures (PRO-PMs)  
623 is promising. This project has built on many years of exemplary work in the field of patient-reported  
624 outcomes and it attempts to lay out concrete steps to advance measurement and use of such data to  
625 the forefront of accountability and performance improvement.

626

## 627 **Notes**

- 628 1. Institute of Medicine, *To Err Is Human: Building a Safer Health System*, Washington, DC: National  
629 Academy Press; 1999.  
630  
631 2. Institute of Medicine, *Crossing the Quality Chasm: A New Health System for the 21st Century*,  
632 Washington, DC: National Academy Press; 2001.  
633  
634 3. Fisher ES, Wennberg DE, Stukel TA, et al., The implications of regional variations in Medicare  
635 spending (parts 1 & 2), *Ann Intern Med*, 2003;138(4):273-298.  
636

637 4. McGlynn EA, Asch SM, Adams J, et al., The quality of health care delivered to adults in the United  
638 States, *NEJM*, 2003;348(26):2635-2645.  
639

640 5. The Commonwealth Fund Commission on a High Performance Health System, *Why Not the Best?*  
641 *Results from the National Scorecard on U.S. Health System Performance, 2011*, New York: The  
642 Commonwealth Fund; 2011.  
643

644 6. Agency for Healthcare Research and Quality (AHRQ), *National Healthcare Disparities and Quality*  
645 *Reports*, Rockville, MD: AHRQ; 2010. Available at [www.ahrq.gov/qual/qrdr10.htm](http://www.ahrq.gov/qual/qrdr10.htm). Last accessed  
646 October 2012.  
647

648 7. Patient Protection and Affordable Care Act, *Pub. L. No. 111-148*, Sec. 3011 (2010).  
649

650 8. Six priority areas of the NQS: Health and well-being, prevention and treatment of leading causes of  
651 mortality, person- and family-centered care, patient safety, effective communication and care  
652 coordination, and affordable care.  
653

654 9. Department of Health and Human Services (HHS), *Report to Congress: National Strategy for Quality*  
655 *Improvement in Health Care*, Washington, DC: HHS; 2011. Available at  
656 [www.healthcare.gov/law/resources/reports/nationalqualitystrategy032011.pdf](http://www.healthcare.gov/law/resources/reports/nationalqualitystrategy032011.pdf). Last accessed  
657 October 2012.  
658

659 10. Department of Health and Human Services (HHS), *Attachment to the Annual Report to Congress:*  
660 *National Strategy for Quality Improvement in Health Care: Agency-Specific Quality Strategic Plans*,  
661 Washington, DC: HHS; 2012. <http://www.ahrq.gov/workingforquality/nqs/nqsplans.pdf>. Last  
662 accessed October 2012.  
663

664 11. Remmers C, Hibbard J, Mosen DM, et al., Is patient activation associated with future health  
665 outcomes and healthcare utilization among patients with diabetes? *J Ambul Care Manage*,  
666 2009;32(4):320-7.  
667

668 12. Weinstein JN, Clay K, Morgan TS, Informed Patient Choice: Patient-Centered Valuing Of Surgical  
669 Risks And Benefits, *Health Affairs*, 2007;26(30):726-730.  
670

671 13. Agency for Healthcare Research and Quality (AHRQ), *Guide to Patient and Family Engagement*  
672 *Environmental Scan Report*, Rockville, MD: AHRQ; 2012. Available at  
673 <http://www.ahrq.gov/qual/ptfamilyscan/ptfamilyscan.pdf>. Last accessed October 2012.  
674

675 14. Conway J, Johnson B, Edgman-Levitan S, et al., *Partnering with Patients and Families To Design a*  
676 *Patient- and Family-Centered Health Care System: A Roadmap for the Future: A Work in Progress*,  
677 Bethesda, MD: Institute for Family-Centered Care; 2006. Available at  
678 <http://www.ipfcc.org/pdf/Roadmap.pdf>. Last accessed October 2012.  
679

680 15. National Technology Transfer and Advancement Act of 1995, *Pub. L. No. 104-113* (1996).  
681

- 682 16. U.S. Food and Drug Administration, Guidance for Industry, Patient-Reported Outcome Measures:  
683 Use in Medical Product Development to Support Labeling Claims, *Fed Regist.* 2009;74(35):65132-  
684 133. [Available here.](#)  
685
- 686 17. Informed Medical Decisions Foundation, *What is Shared Decision Making?* Available at  
687 <http://informedmedicaldecisions.org/what-is-shared-decision-making/>. Last accessed October 2012.

DRAFT

## APPENDICES

### Appendix A—Expert Panel Roster

**\*Patricia Brennan, RN, PhD, FAAN, FACMI (Co-Chair)**

University of Wisconsin-Madison, Madison, WI

**\*Joyce Dubow, MUP (Co-Chair)**

AARP, Washington, DC

**Richard Bankowitz, MBA, MD, FACP**

Premier healthcare alliance, Washington, DC

**Ethan Basch, MD, MSc**

University of North Carolina at Chapel Hill, Chapel Hill, NC

**Jim Bellows, PhD, MPH**

Kaiser Permanente, Oakland, CA

**Laurie Burke, RN**

Food and Drug Administration, Silver Spring, MD

**Jennifer Eames-Huff**

Pacific Business Group on Health, San Francisco, CA

**\*Stephan Fihn, MD, MPH**

Veterans Health Administration, Seattle, Washington

**Floyd Fowler, PhD**

Informed Medical Decision Making Foundation, Boston, MA

**Lori Frank, PhD**

Patient Centered Outcomes Research Institute, Washington, DC

**Theodore Ganiats, MD**

University of California San Diego Health System, La Jolla, CA

**\*Kate Goodrich, MD**

Centers for Medicare & Medicaid Services, Washington, DC

**Judith Hibbard, DrPH**

University of Oregon, Eugene, OR

**Dennis Kaldenberg, PhD**

Press Ganey Associates, South Bend, IN

**Irene Katzan, MD, MS**

Cleveland Clinic, Cleveland, OH

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

**\*Lewis Kazis, Sc.D**

Boston University School of Public Health, Boston, MA

**Uma Kotagal, MSc**

Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**Kevin Larsen, MD, FACP**

Office of the National Coordinator for Health Information Technology, Washington, DC

**Kathleen Lohr, PhD, MPhil, MA**

RTI International, Chapel Hill, NC

**Elizabeth Mort, MD**

Massachusetts General Hospital, Boston, MA

**Charles Moseley, Ed.D.**

National Association of State Directors of Developmental Disabilities Services, Alexandria, VA

**\*Eugene Nelson, DSc, MPH**

Dartmouth- Hitchcock Medical Center, Lebanon, NH

**Kenneth Ottenbacher, PhD, OTR**

The University of Texas Medical Branch at Galveston, Galveston, TX

**\*Greg Pawlson, MD, MPH**

BlueCross BlueShield Association, Washington, DC

**Eleanor Perfetto, PhD**

Pfizer, Washington, DC

**Collette Pitzen, BSN, RN, CPHQ**

Minnesota Community Measurement, Minneapolis, MN

**Cheryl Powell**

Centers for Medicaid & Medicare Services, Baltimore, MD

**David Radley, PhD**

Institute for Healthcare Improvement, Cambridge, MA

**Ted Rooney, RN, MPH**

Maine Quality Counts, Manchester, ME

**Debra Saliba, MD, MPH**

UCLA Borun Center, Los Angeles VA Medical Center, The RAND Corporation, Los Angeles, CA

**Marcel Salive, MD, MPH**

National Institutes of Health, Rockville, MD

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

**Barbara Summers, PhD, RN, FAAN**

University of Texas-MD Anderson Cancer Center, Houston, TX

**Kalahn Taylor-Clark, PhD, MPH, BA**

National Partnership for Women & Families, Washington, DC

**Mary Tinetti, MD**

Yale New Haven Health System, New Haven, CT

**Phyllis Torda, MA**

National Committee for Quality Assurance, Washington, DC

**John Wasson, MD**

Dartmouth Medical School, Lebanon, NH

**Robert Weech-Maldonado, PhD**

University of Alabama at Birmingham, Birmingham, AL

**Linda Wilkinson, MBA**

Dartmouth Hitchcock Medical Center, Lebanon, NH

**Albert Wu, MD, MPH**

Johns Hopkins Health System, Baltimore, MD

“ \* ” Indicates a member of the Planning Committee

**Project Staff**

**Helen Burstin, MD, MPH**

**Karen Adams, PhD**

**Karen Pace, PhD, MSN**

**Gene Cunningham, MS**

**Evan M. Williamson, MPH, MS**

## Appendix B—Characteristics for Selecting PROMs

**Table 4<sup>1</sup>. Important characteristics and best practices to evaluate and select PROs for use in performance measures<sup>279,284</sup>**

	Characteristic	Specific issues to address for performance measures	Example: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) <sup>354</sup> for use in hip arthroplasty
<b>1.</b>	<b>Conceptual and Measurement Model</b>		
	A PRO measure should have documentation defining and describing the concept(s) included and the intended population(s) for use.	<ul style="list-style-type: none"> <li>Target PRO concept should be a high priority for the health care system and patients. Patient engagement should define what is an important concept to patients.</li> <li>Target PRO concept must be actionable in response to the healthcare intervention.</li> </ul>	<ul style="list-style-type: none"> <li>Factorial validity of the physical function and pain subscales has been inadequate.<sup>355</sup></li> </ul>
	There should be documentation of how the concept(s) are organized into a measurement model, including evidence for the dimensionality of the measure, how items relate to each measured concept, and the relationship among concepts.		
<b>2.</b>	<b>Reliability</b>		
	The degree to which an instrument is free from random error.		
<b>2a.</b>	<b>Internal consistency</b> ( <i>multi-item scales</i> )	Classical Test Theory (CTT): <ul style="list-style-type: none"> <li>reliability estimate <math>\geq 0.70</math> for group-level purposes</li> <li>reliability estimate <math>\geq 0.90</math> for individual-level purposes</li> </ul> Item Response Theory: <ul style="list-style-type: none"> <li>item information curves that demonstrate precision<sup>181</sup></li> <li>a formula can be applied to estimate CTT reliability</li> </ul>	<ul style="list-style-type: none"> <li>Cronbach alphas for the three subscales range from 0.86 to 0.98.<sup>356-358</sup></li> </ul>
<b>2b.</b>	<b>Reproducibility</b> ( <i>stability over time</i> ) <ul style="list-style-type: none"> <li>type of test-retest estimate depends on the response scale (dichotomous, nominal ordinal, interval, ratio)</li> </ul>		<ul style="list-style-type: none"> <li>Test-retest reliability has been adequate for the pain and physical function subscales, but less adequate for the stiffness subscale.<sup>358</sup></li> </ul>
<b>3.</b>	<b>Validity</b>		
	The degree to which the instrument reflects what it is	<ul style="list-style-type: none"> <li>There are a limited number of</li> </ul>	

<sup>1</sup> This table is adapted from recommendations contained within a report from the Scientific Advisory Committee of the Medical Outcomes Trust and a report submitted to the PCORI Methodology Committee. The recommendations from these sources have been adapted to enhance relevance to PRO selection for performance measurement.



	Characteristic	Specific issues to address for performance measures	Example: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) <sup>354</sup> for use in hip arthroplasty
	supposed to measure.	PRO instruments that have been validated for performance measurement. <ul style="list-style-type: none"> <li>• PRO instruments should include questions that are patient-centered.</li> </ul>	
<b>3a.</b>	<b>Content Validity</b>		
	The extent to which a measure samples a representative range of the content.		
	A PRO measure should have evidence supporting its content validity, including evidence that patients and/or experts consider the content of the PRO measure relevant and comprehensive for the concept, population, and aim of the measurement application.		<ul style="list-style-type: none"> <li>• Development involved expert clinician input, and survey input from patients,<sup>359</sup> as well as a review of existing measures.</li> </ul>
	Documentation of qualitative and/or quantitative methods used to solicit and confirm attributes (i.e., concepts measured by the items) of the PRO relevant to the measurement application.		
	Documentation of the characteristics of participants included in the evaluation (e.g., race/ethnicity, culture, age, socio-economic status, literacy).		
	Documentation of sources from which items were derived, modified, and prioritized during the PRO measure development process.		
	Justification for the recall period for the measurement application.		
<b>3b.</b>	<b>Construct and Criterion-related Validity</b>		
	A PRO measure should have evidence supporting its construct validity, including: <ul style="list-style-type: none"> <li>• documentation of empirical findings that support predefined hypotheses on the expected associations among measures similar or dissimilar to the measured PRO</li> <li>• documentation of empirical findings that support predefined hypotheses of the expected differences in scores between “known” groups</li> </ul>		<ul style="list-style-type: none"> <li>• Patient ratings of satisfaction with arthroplasty were correlated with WOMAC scores in the expected direction.<sup>22,360,361</sup></li> </ul>
	A PRO measure should have evidence that shows the extent to which scores of the instrument are related to a criterion measure.		
<b>3c.</b>	<b>Responsiveness</b>		
	A PRO measure for use in longitudinal initiatives should have evidence of responsiveness, including empirical evidence of changes in scores consistent with predefined hypotheses regarding changes in the target population.	<ul style="list-style-type: none"> <li>• If a PRO measure has cross-sectional data that provides sufficient evidence in regard to the reliability (internal consistency), content validity, and construct validity but has no data yet on responsiveness over time (i.e., ability of a PRO</li> </ul>	<ul style="list-style-type: none"> <li>• Demonstrates adequate responsiveness and ability to detect change in response to clinical intervention.<sup>362</sup></li> </ul>

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

	<b>Characteristic</b>	<b>Specific issues to address for performance measures</b>	<b>Example: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)<sup>354</sup> for use in hip arthroplasty</b>
		measure to detect changes in the construct being measured over time), would you accept use of the PRO measure to provide valid data over time in a longitudinal study if no other PRO measure was available?	
		<ul style="list-style-type: none"> <li>• Important to emphasize responsiveness because there is an expectation of consequences. Need to be able to demonstrate responsiveness if action is to be taken.</li> </ul>	
		<ul style="list-style-type: none"> <li>• PRO must be sensitive to detect change in response to the specific healthcare intervention</li> </ul>	
<b>4.</b>	<b>Interpretability of Scores</b>		
	<p>A PRO measure should have documentation to support interpretation of scores, including:</p> <ul style="list-style-type: none"> <li>• what low and high scores represent for the measured concept</li> <li>• representative mean(s) and standard deviation(s) in the reference population</li> <li>• guidance on the minimally important difference in scores between groups and/or over time that can be considered meaningful from the patient and/or clinical perspective</li> </ul>	<ul style="list-style-type: none"> <li>• If different PROs are used, it is important to establish a link or cross-walk between them.</li> <li>• Because the criteria for assessing clinically important change in individuals does not directly translate to evaluating clinically important group differences,<sup>327</sup> a useful strategy is to calculate the proportion of patients who experience a clinically significant change<sup>271,327</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Availability of population-based, age- and gender-normative values<sup>363</sup></li> <li>• Availability of minimal clinically important improvement values<sup>364</sup></li> <li>• Can be translated into a utility score for use in economic and accountability evaluations<sup>365</sup></li> </ul>
<b>5.</b>	<b>Burden</b>		
	The time, effort, and other demands on the respondent and the administrator.	<ul style="list-style-type: none"> <li>• In a busy clinic setting, PRO assessment should be as brief as possible, and reporting should be done in real-time.</li> <li>• Patient engagement should inform what constitutes “burden.”</li> </ul>	<ul style="list-style-type: none"> <li>• Short form available<sup>366</sup></li> <li>• Average time to complete mobile phone WOMAC = 4.8 minutes<sup>367</sup></li> </ul>
<b>6.</b>	<b>Alternatives modes and methods of administration</b>	<ul style="list-style-type: none"> <li>• The use of multiple modes and methods can be useful for diverse populations. However, there should be evidence regarding their equivalence.</li> </ul>	<ul style="list-style-type: none"> <li>• Validated mobile phone and touchscreen based platforms<sup>368,369</sup></li> </ul>

NQF DRAFT-DO NOT CITE OR QUOTE

NQF MEMBER and PUBLIC comments are due November 23, 2012 by 6:00 PM ET

	Characteristic	Specific issues to address for performance measures	Example: The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) <sup>354</sup> for use in hip arthroplasty
7.	Cultural and language adaptations	<ul style="list-style-type: none"> <li>The mode, method and question wording must yield equivalent estimates of PRO measures.</li> </ul>	<ul style="list-style-type: none"> <li>Available in over 65 languages<sup>370</sup></li> </ul>
8.	Electronic health records (EHR)	Critical features: <ul style="list-style-type: none"> <li>interoperability</li> <li>automated, real-time measurement and reporting</li> <li>sophisticated analytic capacities</li> </ul>	<ul style="list-style-type: none"> <li>Electronic data capture may allow for integration within EHR<sup>367</sup></li> </ul>

DRAFT

## Appendix C—Glossary

**Patient-reported outcome (PRO):** The concept of any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else. PRO domains included in this project encompass:

- health-related quality of life including functional status;
- symptom and symptom burden;
- experience with care; and
- health-related behaviors.

**PRO measure (PROM):** Instrument, scale, or single-item measure used to assess the PRO concept as perceived by the patient, obtained by directly asking the patient to self-report (e.g., PHQ-9).

**Performance measure:** Numeric quantification of healthcare quality for a designated accountable healthcare entity, such as hospital, health plan, nursing home, clinician, etc.

**PRO-based performance measure (PRO-PM):** A performance measure that is based on PROM data aggregated for an accountable healthcare entity (e.g., percentage of patients in an accountable care organization whose depression score as measured by the PHQ-9 improved

DRAFT